Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease

Surgical Neurology

Volumn 72, Issue 5, 2009, Pages 476-480

  Fujimura, Miki ^a   Watanabe, Mika ^a   Narisawa, Ayumi ^a   Shimizu, Hiroaki ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Enzyme linked immunosorbent assay; Immunohistochemistry; Matrix metalloproteinase; Moyamoya disease

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; ANGIOGENESIS; ARACHNOID; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MOYAMOYA DISEASE; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; ARACHNOID; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; CEREBROVASCULAR CIRCULATION; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MOYAMOYA DISEASE; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UP-REGULATION; YOUNG ADULT;

EID: 71049172538     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surneu.2008.10.009     Document Type: Article

References (17)

1. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., and Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842 (1999) 92-100
2. Fujimura M., Watanabe M., Shimizu H., and Tominaga T. Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: immunohistochemical analysis of MMP-2, -9 and TIMP-2. Acta Neurochir (Wien) 149 (2007) 179-183
3. Fujimura M., Kaneta T., Mugikura S., Shimizu H., and Tominaga T. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 67 (2007) 273-282
4. Fujimura M., Shimizu H., Mugikura S., and Tominaga T. Delayed intracerebral hemorrhage after superficial temporal artery-middle cerebral artery anastomosis in a patients with moyamoya disease: possible involvement of cerebral hyperperfusion and increased vascular permeability. Surg Neurol (2008) [electronic publication ahead of print]
5. Fujimura M., Mugikura S., Kaneta T., Shimizu H., and Tominaga T. Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol (2008) [electronic publication ahead of print]
6. Ikezaki K., Kono S., and Fukui M. In: Ikezaki K., and Loftus C.M. (Eds). Etiology of moyamoya disease: pathology, pathophysiology, and genetics (2001), AANS PRESS, Rolling Meadows (Ill) 55-64
7. Kang H.S., Kim S.K., Kim Y.Y., Hwang Y.S., and Wang K.C. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 58 (2006) 1074-1080
8. Lee C.Z., Xu B., Hashimoto T., McCulloch C.E., Yang G.Y., and Young W.L. MMP and angiogenesis doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 35 (2004) 1715-1719
9. Lee C.Z., Xue Z., Zhu Y., Yang G.Y., and Young W.L. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke 38 (2007) 2563-2568
10. Mauro A.J., Johnson E.S., and Chikos P.M. Lipohyalinosis and miliary microaneurysms causing hemorrhage in a patient with moyamoya disease: a clinicopathological study. Stroke 11 (1980) 405-412
11. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribó M., Quintana M., and Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107 (2003) 598-603
12. Ogasawara K., Komoribayashi N., Kobayashi M., Fukuda T., Inoue T., Yamada K., et al. Neural damage caused by cerebral hyperperfusion after arterial bypass surgery in a patient with moyamoya disease: case report. Neurosurgery 56 (2005) E1380
13. Rosenberg G.A., and Navratil M. Metalloproteinases inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48 (1997) 921-926
14. Suzuki J., and Takaku A. Cerebrovascular 'moyamoya' disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 (1969) 288-299
15. Wang X., Jung J., Asahi M., Chwang W., Russo L., Moskowitz M.A., Dixon C.E., Fini M.E., and Lo E.H. Effects of matrix metalloproteinase 9 gene knockout on morphological and motor outcomes after traumatic brain injury. J Neurosci 20 (2000) 7037-7043
16. Yoshida Y., Yoshimoto T., Shirane R., and Sakurai Y. Clinical course, surgical management, and long-term outcome of moyamoya patients with rebleeding after an episode of intracerebral hemorrhage: an extensive follow-up study. Stroke 30 (1999) 2272-2276
17. Zhang B., Dhillon S., Geary I., Howell W.M., Iannotti F., Day I.N., and Ye S. Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage. Stroke 32 (2001) 2198-2202